Breast Clinical Trials
Delivering quality care through clinical trials
Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.
Agendia - (FLEX Study)
Study Phase: Observational - Registry
Condition(s): Stage I-III breast cancer
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry
ClinicalTrials.gov NCT ID: NCT03053193
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Eli Lilly J6M-MC-JSGD (PIKALO-2)
Study Phase: Phase III
Condition(s): HR+, HER2-, PIK3CA mutated advanced breast cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer
ClinicalTrials.gov NCT ID: NCT07174336
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Prelude Dx - 20172841 - (The Predict Registry)
Study Phase: Observational - Registry
Condition(s): Ductal Carcinoma In Situ
A Prospective Study to Evaluate the Effect of DCISionRT Test on Treatment Decisions in Patients with DCIS following Breast-Conserving Therapy (The Predict Registry)
ClinicalTrials.gov NCT ID: NCT03448926
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
SWOG - S2206
Study Phase: Phase III - Drug
Condition(s): Stage II-III Breast Cancer
Phase III Trials of Neoadjuvant Durvalumab plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
ClinicalTrials.gov NCT ID: NCT06058377
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
SWOG - S2212
Study Phase: Phase III
Condition(s): Early stage, triple negative breast cancer
Shorter Anthracycline-free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer, A Randomized Phase III Study (SCARLET)
ClinicalTrials.gov NCT ID: NCT05929768
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.
